Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis
- PMID: 16805890
- DOI: 10.1111/j.1542-4758.2006.00109.x
Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis
Abstract
An elevated calcium x phosphate product (Ca x P) is an independent risk factor for vascular calcification and cardiovascular death in dialysis patients. More physiological dialysis in patients undergoing nocturnal hemodialysis (NHD) has been shown to produce biochemical advantages compared with conventional hemodialysis (CHD) including superior phosphate (P) control. Benefits of dialysate with greater calcium (Ca) concentration are also reported in NHD to prevent Ca depletion and subsequent hyperparathyroidism, but there are concerns that a higher dialysate Ca concentration may contribute to raised serum Ca levels and greater Ca x P and vascular disease. The NHD program at our unit has been established for 4 years, and we retrospectively analyzed Ca and P metabolism in patients undergoing NHD (8-9 h/night, 6 nights/week). Our cohort consists of 11 patients, mean age 49.3 years, who had been on NHD for a minimum of 12 months, mean 34.3 months. Commencement was with low-flux (LF) NHD and 1.5 mmol/L Ca dialysate concentration, with conversion to high-flux (HF) dialyzers after a period (mean duration 18.7 months). We compared predialysis serum albumin, intact parathyroid hormone, P, total corrected Ca, and Ca x P at baseline on CHD, after conversion to LF NHD and during HF NHD. We also prospectively measured bone mineral density (BMD) on all patients entering the NHD program. Bone densitometry (DEXA) scans were performed at baseline (on CHD) and yearly after commencement of NHD. With the introduction of HF dialyzers, the Ca dialysate concentration was concurrently raised to 1.75 mmol/L after demonstration on DEXA scans of worsening osteopenia. Analysis of BMD, for all parameters, revealed a decrease over the first 12 to 24 months (N = 11). When the dialysate Ca bath was increased, the median T and Z scores subsequently increased (data at 3 years, N = 6). The mean predialysis P levels were significantly lower on LF NHD vs. CHD (1.51 vs. 1.77 mmol/L, p = 0.014), while on HF NHD P was lower again (1.33 mmol/L, p = 0.001 vs. CHD). Predialysis Ca levels decreased with conversion from CHD to LF NHD (2.58 vs. 2.47 mmol/L, p = 0.018) using a 1.5 mmol/L dialysate Ca concentration. The mean Ca x P on CHD was 4.56 compared with a significant reduction of 3.74 on LF NHD (p = 0.006) and 3.28 on HF NHD (p = 0.001 vs. CHD), despite the higher dialysate Ca in the latter. We conclude that an elevated dialysate Ca concentration is required to prevent osteopenia. With concerns that prolonged higher Ca levels contribute to increased cardiovascular mortality, the optimal Ca dialysate bath is still unknown. Better P control on NHD, however, reduces the overall Ca x P, despite the increased Ca concentration, therefore reducing the risk of vascular calcification.
Similar articles
-
Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.Hemodial Int. 2007 Apr;11(2):217-24. doi: 10.1111/j.1542-4758.2007.00172.x. Hemodial Int. 2007. PMID: 17403174
-
High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.Nephrol Dial Transplant. 1996 Aug;11(8):1586-91. Nephrol Dial Transplant. 1996. PMID: 8856216
-
Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium.Bone. 2007 Oct;41(4):698-703. doi: 10.1016/j.bone.2007.06.014. Epub 2007 Jun 29. Bone. 2007. PMID: 17643363 Clinical Trial.
-
Review of dialysate calcium concentration in hemodialysis.Hemodial Int. 2006 Oct;10(4):326-37. doi: 10.1111/j.1542-4758.2006.00125.x. Hemodial Int. 2006. PMID: 17014507 Review.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
Choices in hemodialysis therapies: variants, personalized therapy and application of evidence-based medicine.Clin Kidney J. 2021 Dec 27;14(Suppl 4):i45-i58. doi: 10.1093/ckj/sfab198. eCollection 2021 Dec. Clin Kidney J. 2021. PMID: 34987785 Free PMC article. Review.
-
Bioimpacts of dialyzer variety on phosphorus level in Iranian hemodialysis patients.J Renal Inj Prev. 2016 May 30;5(2):94-7. doi: 10.15171/jrip.2016.20. eCollection 2016. J Renal Inj Prev. 2016. PMID: 27471742 Free PMC article.
-
Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.PLoS One. 2016 Jun 8;11(6):e0156891. doi: 10.1371/journal.pone.0156891. eCollection 2016. PLoS One. 2016. PMID: 27276077 Free PMC article.
-
Low calcium dialysate combined with CaCO3 in hyperphosphatemia in hemodialysis patients.Exp Ther Med. 2013 Jun;5(6):1732-1736. doi: 10.3892/etm.2013.1067. Epub 2013 Apr 17. Exp Ther Med. 2013. PMID: 23837063 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous